KALA BIO Implements 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance

KALA BIO, Inc. (NASDAQ: KALA) has executed a 1-for-50 reverse stock split of its common stock, effective at 4:05 p.m. on May 8, 2026. The split-adjusted shares will begin trading on the Nasdaq Capital Market at the open on May 11, 2026. The move reduces the company’s outstanding common shares from approximately 929.5 million to 18.6 million, with cash payments issued in lieu of fractional shares and proportional adjustments made to outstanding equity awards, warrants, and other convertible securities.

The reverse stock split is a strategic maneuver to increase the per-share trading price of KALA’s stock, which had fallen to penny stock levels. By consolidating shares, the company aims to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. This action is critical for KALA as it seeks to maintain its listing status and attract institutional investors who often avoid stocks trading below certain thresholds.

KALA BIO describes itself as a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. Its dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations to unlock the value of their proprietary biological data without surrendering control.

The company’s platform, Researgency.ai, is designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. Kala’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector. However, the reverse stock split raises questions about the company’s financial health and market confidence. While the split does not change the company’s underlying value, it often signals that a company’s stock price has declined significantly, which can be a red flag for investors.

For KALA, the split is a necessary step to stabilize its stock price and maintain its Nasdaq listing. The company’s ability to execute its AI infrastructure strategy and advance its biologics pipeline will be crucial for long-term value creation. Investors will be watching closely to see if the split can help KALA regain traction and attract new capital. The company’s success hinges on its ability to commercialize its AI platform and bring its drug candidates to market, both of which require substantial funding and market confidence.

More information about KALA BIO and its reverse stock split can be found in the full press release at https://ibn.fm/yUznR. For details about the company’s AI platform, visit https://www.researgency.ai/.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is KALA BIO Implements 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance.

The post KALA BIO Implements 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance appeared first on citybuzz.